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Abstract
Persistence of HIV-1 reservoirs within the Central Nervous System (CNS) remains a significant challenge to the efficacy of
potent anti-HIV-1 drugs. The primary human Brain Microvascular Endothelial Cells (HBMVEC) constitutes the Blood Brain
Barrier (BBB) which interferes with anti-HIV drug delivery into the CNS. The ATP binding cassette (ABC) transporters
expressed on HBMVEC can efflux HIV-1 protease inhibitors (HPI), enabling the persistence of HIV-1 in CNS. Constitutive low
level expression of several ABC-transporters, such as MDR1 (a.k.a. P-gp) and MRPs are documented in HBMVEC. Although it
is recognized that inflammatory cytokines and exposure to xenobiotic drug substrates (e.g HPI) can augment the expression
of these transporters, it is not known whether concomitant exposure to virus and anti-retroviral drugs can increase drug-
efflux functions in HBMVEC. Our in vitro studies showed that exposure of HBMVEC to HIV-1 significantly up-regulates both
MDR1 gene expression and protein levels; however, no significant increases in either MRP-1 or MRP-2 were observed.
Furthermore, calcein-AM dye-efflux assays using HBMVEC showed that, compared to virus exposure alone, the MDR1
mediated drug-efflux function was significantly induced following concomitant exposure to both HIV-1 and saquinavir
(SQV). This increase in MDR1 mediated drug-efflux was further substantiated via increased intracellular retention of
radiolabeled [3H-] SQV. The crucial role of MDR1 in 3H-SQV efflux from HBMVEC was further confirmed by using both a
MDR1 specific blocker (PSC-833) and MDR1 specific siRNAs. Therefore, MDR1 specific drug-efflux function increases in
HBMVEC following co-exposure to HIV-1 and SQV which can reduce the penetration of HPIs into the infected brain
reservoirs of HIV-1. A targeted suppression of MDR1 in the BBB may thus provide a novel strategy to suppress residual viral
replication in the CNS, by augmenting the therapeutic efficacy of HAART drugs.
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Introduction
Being a lentivirus, HIV-1 infection shows a long latency period
and slow disease progression resulting in severe immune deficien-
cies and ultimately AIDS. HIV-1 primarily infects CD4+ T-
lymphocytes, but long-term persistence of the virus occurs in
monocytes and macrophages, e.g. in microglial cells within the
CNS. Thus, the sequestered sites within the brain can act as
anatomical reservoirs for HIV-1 which prevents complete
eradication of the virus despite long-term anti-retroviral therapy
[1–3]. The Highly Active Antiretroviral Therapy (HAART) which
is highly effective in suppressing serum viral load, cannot
effectively suppress productive infection in these reservoirs. In
the brain, one of the strategies via which HIV-1 can evade
HAART efficacy is due to the presence of drug-efflux transporters
on the BBB endothelial cells (EC) [4]. All of the currently available
HIV-1 protease inhibitors (HPI) are known to be substrates of
different ABC-transporters, and are actively effluxed from the BBB
via both MDR1 (P-gp) and the multidrug resistance associated
proteins (MRP-1 and MRP-2) [5,6]. Although several competitive
inhibitors of these transporters are being tested as an approach to
increase HPI levels within the brain, their generalized inhibition
has not been a safe and feasible approach since these drug-efflux
pumps play crucial physiologic roles in protecting the CNS and
other organs from toxic xenobiotics [7]. Therefore, a clear
understanding of the molecular mechanism of ABC-transporter
expression in HIV-infected brain microenvironments may provide
novel strategies towards alternative treatment options such as their
specific inhibition via gene therapy approaches.
Our previous studies demonstrated that these transporters are
present in the ECs of different tissues including the BBB, and are
responsible for the efflux of different anti-HIV-1 medications,
especially the HPIs and the Nucleoside Reverse Transcriptase
Inhibitors (NRTIs) [8]. Previous publications have also suggested
that the HIV-1 transactivator (Tat) protein and/or HIV-1 induced
inflammatory cytokines (e.g. TNF-a IL-1b etc.) can enhance the
expression of different ABC transporters [9–11]. Nonetheless, very
little is known about the specific drug transporters involved in
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drug-efflux from the BBB in HIV-1 infected microenvironments
and their effector mechanisms which ultimately results in lower
HAART levels within the CNS.
In the current study, an in vitro model of the BBB was adopted
by utilizing primary HBMVEC, where we have documented
changes in expression of both MDR1 and MRPs in cells exposed
to HIV-1 and/or saquinavir (SQV) [12]. Furthermore, using
different ABC-transporter inhibitors, e.g. verapamil, MK-571 and
PSC-833, we have observed significant changes in the efflux
function of both MDR1 and MRPs. We also demonstrated the
dominant role of MDR1 in saquinavir efflux from HIV-1-exposed
HBMVEC. Our findings implicate the therapeutic potential of
specifically suppressing MDR1 expression to increase HAART
entry into HIV-1-infected regions of the brain.
Materials and Methods
Reagent
The fluorescent dye Calcein acetoxy-methyl ester (Calcein-AM)
was obtained from Molecular Probes (Eugene, OR). The dual
inhibitor, verapamil and the MRP inhibitor, MK571 were
purchased from Cal-biochem (San Diego, CA). The P-gp specific
inhibitor, PSC-833 was purchased from Xenotech (Lenexa, KS).
Radio-labeled [3H]-saquinavir (3H-SQV) was obtained from
Moravek Biochemicals (Brea, CA) and unlabeled saquinavir
mesylate (InviraseTM) was obtained from Tulane University
hospital pharmacy (New Orleans, LA). The TrizolTM reagent for
RNA isolation was obtained from Invitrogen (Carlsbad, CA) and
diethylpyrocarbonate (DEPC) treated water was purchased from
Ambion (Austin, TX). Reagents for reverse transcription (RT), e.g.
M-MLV reverse transcriptase, oligo deoxythymidine (oligo-dT)
primers and RNAase inhibitor, were purchased from Promega
(Madison, WI). All other Polymerase Chain Reaction (PCR)
reagents, such as buffers, deoxy-nucleotide triphosphates (dNTPs)
and the Taq DNA-polymerase were obtained from Sigma Aldrich
(St. Louis, MO). The PCR primers were synthesized from
Midland Certified Reagent Company (Midland, TX). Cell lysis
buffer for protein isolation was obtained from Cell Signaling
(Danvers, MA) and the BCA protein assay kit was purchased from
Pierce (Rockford, IL). Mouse monoclonal anti-MDR1 (P-gp)
antibody (Clone #C-219) was purchased from Abcam Inc.
(Cambridge, MA) and the goat anti-mouse secondary antibody
(A9044) was obtained from Sigma. The PKC pathway stimulator
phorbol-12-myristate-13-acetate (PMA) was also obtained from
Sigma. For immunocytochemistry studies, Alexa fluor-488 conju-
gated goat anti-mouse antibody and Prolong antifade reagent,
were both purchased from Invitrogen (Grand Island, NY). The
control and MDR1 specific short interfering RNAs (siRNA) and
transfection reagents were obtained from Dharmacon (Lafayette,
Co). The HIV-1 p24 Antigen Capture ELISA kit was purchased
from ZeptoMetrix Corporation (Buffalo, USA).
Cell Culturing
The primary brain endothelial cells (HBMVEC), cell culture
media, cell attachment factor and cell passage reagents were all
purchased from Cell Systems (CS-C) (Kirkland, WA). The
HBMVEC were maintained in CS-C Complete medium, accord-
ing to the supplier’s recommendations, in a 37uC incubator with
5% CO2. For experiments, the HBMVEC were plated in 75 cm
2
flasks coated with CS-C Attachment Factor and cultured in CS-C
media containing 10% fetal bovine serum (FBS), CS-C Growth
Factor and 2% gentamycin sulfate. Experiments were conducted
within cell passages 4–6. At these passages, cells displayed
cobblestone appearance which is morphologically correct for
ECs. All treatments were performed after cells were 60–70%
confluent. The HuT78 T-lymphocytic cell line was obtained from
American Type Culture Collection (ATCC, Manassas, VA) and
the HTLV-IIIB (HIV-1-infected H-9 T-cells) (Cat. No. -398) was
obtained from NIH AIDS Reagent Program (Germantown, MD,
USA). Both lymphocytic cell lines were maintained in RPMI-1640
medium containing 10% FBS and 2% penicillin/streptomycin,
and up to passages 12–15 were used for all experiments. To
confirm the consistent productive infection in these T-cells,
supernatants from infected cells were regularly monitored for
HIV-1 p24 levels by ELISA.
Virus Preparation, Infection and Heat Inactivation
Cell-free viral stock was obtained by harvesting the supernatants
of HTLV-IIIB cells, centrifugation at 10,000 rpm for 10 min and
filtration through a 0.2 m filters. The concentration of viral
particles was determined by p24 ELISA and all HIV-1 exposure
studies were performed with viral inoculums of 0.2 or 1.0
multiplicity of infection (MOI) where a stock concentration of
,100 pg/ml p24 was designated as 1.0 MOI. Heat inactivation of
HIV-1 was performed by heating the cell free viral stocks at 65uC
for 45 min, and the absence of infectious virus after heat
inactivation was corroborated by incubation with uninfected
HuT78 cells followed by p24 ELISA at 3 and 5 days post infection
[13].
Preparation of the Blood Brain Barrier Model
The HBMVEC were seeded on 0.4 mm pore size PTFE
(Polytetrafluoroethylene) membrane tissue culture inserts (Corn-
ing, NY) at the initial concentration of 104 cells/well, as previously
described [12]. For infection experiment, HBMVEC were allowed
to grow up to 70% confluency and then the viral inoculum was
added to the upper chamber of the trans-well inserts. After 24 hrs
of incubation, HBMVEC were washed thoroughly with sterile
PBS and replenished with fresh media. For drug exposures, i.e.
saquinavir, verapamil, MK-571 or PSC-833, all drugs were added
to the upper chamber of the trans-well inserts, at the specified
times and for the specified durations and cells were harvested at
different time points for mRNA and protein isolation as well as for
fluorescence microscopy. At the beginning of each experiment,
and at different times post-exposure, quantitation of HIV-1 viral
particles in the culture supernantants was analyzed via p24
ELISA.
Calcein-AM Efflux Assays
Calcein-AM, a lipid-soluble dye and a known substrate for both
MDR1 and MRP transporters, was used to determine MDR1 and
MRP-mediated efflux functions (Molecular Probes; Eugene, OR)
[14,15]. Upon entering cells, endogenous esterase cleaves calcein-
AM to form the hydrophobic fluorescent calcein. ABC-transport-
ers cause rapid efflux of the dye prior to esterification and
intracellular calcein-AM florescence can be increased in presence
of ABC-transporter inhibitors, e.g. verapamil or MK-571. Hence,
intracellular retention of this fluorochrome is inversely propor-
tional to the extent of cellular efflux and the effect of inhibitors
indicates the contribution of different transporters. For this assay,
HBMVEC were cultured in 24-well opaque black plates (Krystal,
Labnet, NJ) and treatments such as virus and drug exposures were
carried out as in previous section. To monitor effects on drug-
efflux function, cells were incubated for 15 min with verapamil or
MK-571 (50 mM) at 37uC. Calcein-AM (0.25 mM) was then added
to cells and incubated at 37uC for 15 min in the dark, followed by
three washes with ice-cold phosphate buffered saline (PBS).
Intracellular calcein-AM fluorescence (retention) was determined
HIV-1 Exposure on MDR-1 Efflux Function
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using a FLx800 fluorimeter (Bio-Tek instruments) with absorption
and emission wavelengths set at 485620 nm and 528620 nm,
respectively. Subsequently, cell lysis was done by adding 1X lysis
buffer (30 ml) to each well for 10 min and the extracted proteins
were quantified using the BCA protein assay kit (Thermo
Scientific, IL, USA). Fluorescence measurements obtained from
each well were normalized to the protein concentration in the
respective samples and are represented as fluorescence/mg of
protein. Differences in calcein-AM retention with and without
verapamil or MK-571 indicated the efflux function in control and
virus and/or drug exposed HBMVEC.
RNA Isolation and Semi-quantitative RT-PCR Assays
Total RNA was isolated from cells using the TrizolTM reagent
(Invitrogen; Carlsbad, CA) according to the manufacturer’s
instructions. The RNA concentrations were quantified using a
spectrophotometer to determine the absorbance at 260 nm and
purity was verified by the 260/280 nm absorbance ratio. RNA
aliquots were frozen at 280uC for later use in reverse transcriptase
polymerase chain reaction (RT-PCR) assays. Briefly, total RNA
(2 mg) was first subjected to first-strand cDNA synthesis using a
high capacity cDNA reverse transcription kit (Applied Biosystem,
USA) using the murine leukemia virus (MuLV) RT enzyme
(0.5 U), Oligo-dT (2.4 mg/ml), and dNTPs (100 mM) and
incubation at 42uC for 60 min. For each PCR amplification
reaction, 3 ml of this RT-product was used which were carried out
by using a thermal cycler from Perkin Elmer (Boston, MA; Model
9600) in the presence of Taq DNA-polymerase (0.5 U) in RED-
Taq PCR buffer, containing KCl (500 mM), MgCl2 (11 mM),
dNTPs (200 mM) and the gene-specific primers. The primer
sequences and amplification conditions for MDR1, MRP-1 and
MRP-2 were according to Hua et al (2005) [16] and for GAPDH
according to Konig et al (2005) [17]. The PCR products were
electrophoresed on a 2.0% agarose gel containing ethidium
bromide (10 mg/ml) along with a molecular weight marker DNA
ladder (100–3000 bp) (SM-0243; Fermentas, USA). Band inten-
sities for PCR products were determined by densitometry by using
a GS-700 imaging densitometer (Bio-Rad). The intensity of
amplified ABC-transporter mRNAs were normalized to the values
obtained with GAPDH mRNA in each sample.
Quantitative RT-PCR Assays
Qantitative PCR assays using SyBR Green dye was performed
with a Perkin-Elmer 7700 thermal cycler. Briefly, total RNA was
extracted and quantified as described above. For quantification of
each ABC transporter, 10 ml of reaction mixture containing RNA
(2 mg) was added to each well of a 96-well optical reaction plate
(Applied Biosystems, USA). Primer sequences and amplification
protocols for quantitative analysis of MDR1 and GAPDH
(internal control) mRNA levels were as previously published
[18], which was as follows: 2 min at 50uC, 10 min at 95uC,
followed by 45 cycles of 15 sec at 95uC and 1 min at 60uC. Post
run calculations were done according to the manufacturer’s
software. The obtained Ct values for each ABC transporters
(MDR1, MRP-1, MRP-2 & MRP-3) in both control and HIV-1
and/or SQV exposed HBMVEC, were normalized with GAPDH
mRNA levels. The Ct values were further normalized to each of
the transporter genes in uninfected control cells and graphical
presentation of delta-delta (DD) Ct values are displayed as the
normalized fold changes.
Saquinavir Accumulation Assays
Tritium (3H-) labeled SQV was used to measure the intracel-
lular accumulations of this HPI in control and HIV-1 exposed
HBMVEC. A non-specific inhibitor, verapamil and a MDR1
specific inhibitor PSC-833, were used to determine the efflux rates
of 3H-SQV from cells. Briefly, cells were grown to 70% confluency
in 24-well culture plates and were exposed to HIV-1 and/or SQV
for the indicated time points. To measure efflux rates, cells were
first incubated with verapamil or PSC-833 (50 mM) for 15 min,
followed by a 2 hr exposure to 3H-SQV (1.7 pM; specific activity:
1.0 Ci/mMol). To determine the intracellular retentions, in the
presence or absence of MDR-specific inhibitors, cells were washed
twice with ice cold PBS and cell extracts were obtained by lysing
cells with 1.0 ml of NH4OH (1.0 M) for 5 min. Approximately
500 ml of cell extracts were transferred to scintillation vials
containing 10 ml of Ecolite scintillation cocktail and 200 ml of
extracts were used to measure total protein levels. The counts per
minute (CPM) values in cell extracts were determined with a Tri-
Carb 2800TR Liquid Scintillation counter (Perkin Elmer, USA)
and the data were normalized to the protein contents in respective
samples, and represented as CPM/mg of protein. Differences in
3H-SQV retention with and without verapamil or PSC-833
demonstrated drug-efflux rates in control, and in SQV and/or
HIV-1 exposed HBMVEC.
Western Blot Analysis
The HBMVEC were grown in 10 cm cell culture dishes coated
with collagen, exposed to HIV-1 and/or SQV for the indicated
concentrations and times, and washed twice with PBS before
harvesting proteins using ice-cold lysis buffer. Equal amounts of
proteins (60 mg) were loaded in 7.5% polyacrylamide (SDS-PAGE)
gels and subsequently transferred to a nitrocellulose membrane.
For hybridization, membranes were first incubated with 5% milk
for 1 hr, washed, and incubated overnight at 4uC with a mouse
monoclonal anti-human antibody against MDR1 (C-219, Abcam,
CA) at a 1:200 dilution. After incubation, membranes were
thoroughly washed and incubated with Horseradish peroxidase
(HRP) conjugated goat anti-mouse secondary antibody (1:5000
dilution) for 1 hr. A rabbit anti b-actin antibody (Sigma, USA) was
used as internal control (1:8000 dilutions). HRP was detected by
using a chemiluminescent detection system (LumiGLO, Gaithers-
burg, MD). Densitometric analysis of the respective protein bands
was performed using a imaging software (Bio-Rad).
Immunofluorescent Microscopy
Cells were grown on collagen-I coated four chambered slides
(BD Biosciences) to approximately 60–70% confluency and then
processed as published previously [19]. Following their exposure to
HIV-1 and/or SQV for 24 hrs, cells were incubated with MDR-1
specific primary antibody and then with FITC-conjugated
secondary antibody. Cell nuclei were visualized with 49,6-
diamidino-2-phenylindole hydrochloride (DAPI) (Molecular
Probes, Eugene, OR) and a wheat gram agglutinin (WGA)
conjugated to AlexaFluor-555 (Molecular Probes, USA) was used
as a cell surface marker. Primary antibodies were used at a dilution
of 1:20 and secondary antibodies at 1:200 dilution. Images were
acquired with a Zeiss Axioplan II microscope (Carl Zeiss,
Thornwood, NY). A series of horizontal optical sections (0.3 mm
each) were collected and subsequently deconvolved using Slide-
book 4.1 (Intelligent Imaging Innovations, Denver, CO) or
Volocity (Improvision, Lexington MA) softwares. Images represent
a merging of 10–15 sections (3–4.5 mm). Post-collection processing
of the images was performed using Adobe PhotoShop.
siRNA Transfection
The HBMVEC were transfected with either a non-specific
(random) or a MDR1-specific siRNA cocktail (smart pool) and
HIV-1 Exposure on MDR-1 Efflux Function
PLOS ONE | www.plosone.org 3 October 2013 | Volume 8 | Issue 10 | e75374
siRNA transfection reagents (Dharmacon, USA) and according to
the manufacturer’s instructions. Briey, cells were seeded in six-well
plates at a density of 16105 cells per well until 70% conuent. Cells
were then treated with HIV-1 (0.2 MOI) and SQV (0.3 mM) for
24 hrs. Following the incubation, cells were washed with complete
medium (antibiotic-free). Required concentrations of siRNA and
transfection reagent were prepared separately, mixed together for
15 min and added to the cells containing 2 ml media for 24 hrs
and incubation at 37uC with 5% CO2. Four types of established
MDR1-specific siRNAs (30 nM each) were used as the smart pool.
Random siRNA oligos and GAPDH siRNAs were used as
negative and positive controls, respectively. After incubation, one
set of cells were harvested for RNA extraction, cDNA was
synthesized with respective RNA samples and RT-PCR was
carried out, as described previously. To perform quantitative PCR
amplifications, serial dilutions of each cDNA samples were used.
GAPDH was used as an internal control. The Ct values were
calculated for each sample and graphical representations were
done with respect to percentage inhibition of MDR1 gene with
30 nM siRNA compared to control (untreated) cells. Parallel wells
containing siRNA transfected HBMVEC were also analyzed for
changes in drug-efflux functions using calcein-AM, as previously
described.
Statistical Analysis
All statistical analyses were carried out using the INSTAT-2
software (Graph Pad, San Diego, CA). Each treatment condition
consisted of three to four replicates and each experiment was
performed at least three to five times. Data obtained were used to
calculate the standard error of means (6 SEM). Significant
changes from control values were determined by using a two-tailed
student’s t-test and comparison between three or more groups was
carried out by one-way analysis of variance (ANOVA).
Results
MDR1 Gene Expression Significantly Increased in
HBMVEC Following Exposure to HIV-1
To elucidate the transporters which are mainly involved in drug
efflux in the HBMVEC, cells were exposed to HIV-1 (0.2 or
1.0 MOI) for 6 hrs. The real-time RT-PCR showed a 12–18 fold
increase in MDR1 gene expression within 6 hrs post exposure to
cell free virus. However, the MRP1 and MRP2 expressions were
only increased by 1.5 to 2 folds (Fig. 1A). Furthermore, the drug-
efflux function in HIV-1 exposed HBMVEC was determined after
24 hrs post virus exposure by calcein-AM retention assay (Fig. 1B).
Exposure to either the dual (P-gp and MRP) inhibitor, verapamil
or the MRP-specific inhibitor, MK571 (50 mM each) increased
intracellular fluorescence in control cells, suggesting a constitutive
low level of drug-efflux function in HBMVEC. Interestingly, even
though virus exposure had resulted in significant increases in
MDR1 and MRP gene expressions, the drug efflux function via
these transporters were not significantly augmented, as apparent
from minimal changes in calcein-AM retention as compared to
control cells (Fig. 1B). Therefore, for the rest of our studies, further
characterization of HIV-1 induced changes in drug-efflux function
was focused on MDR1 only.
In order to find out whether the virus alone, virus-induced
inflammatory cytokines, or host cellular factors, are responsible for
the augmenting effects on MDR1 gene expression, the HBMVEC
were exposed to culture media from unstimulated or PMA-
stimulated Hut78 cells, or with cell free virus which was heat
inactivated. MDR1 gene expression was significantly higher (3.3
fold) only when HBMVEC were exposed to live virus, but not with
either the heat-inactivated viral supernatant or the PMA-
stimulated culture supernatants (Fig. 1, C & D). This clearly
indicated the direct role of infectious virus in increasing MDR1
gene expression in HBMVEC.
Both MDR1 Protein Level and MDR-1 Mediated Drug-
efflux were Increased in HBMVEC Following Co-exposure
to HIV-1 and Saquinavir
In order to observe the combined effects of s infectious HIV-1
and the anti-HIV drug, saquinavir (SQV) on MDR1 expression
and efflux function, cells were exposed to HIV-1 (0.2 MOI) alone
and in the presence of SQV (0.3 or 1.0 mM). The fold change
values on MDR1 gene expression, normalized with GAPDH
expression, showed that exposure to even low MOI of HIV-1
increases MDR1 mRNA levels, whereas the combined effect of
HIV-1 and SQV (1 mM) showed much higher induction of the
MDR1 gene (Fig. 2A & 2B). The densitometry analysis also
indicated that with increasing concentration of SQV, MDR1 gene
expression successively increased along with co-exposure of HIV-1
(Fig. 2B). We investigated whether the MDR1 gene activation was
translated to increased protein levels. Western blot analysis showed
that, compared to control (untreated) cells, there was an increase
in protein expression following exposure to SQV (0.3 mM) and
HIV-1 (0.2 MOI), both separately and in combination (Fig. 2C).
To obtain fold-change ratios, protein expression from untreated
samples were empirically designated as 1.0. Exposure to SQV and
virus showed almost 1.6-fold increase in protein levels, but in
combination showed approximately 5.9-fold increase in MDR1
protein level (Fig. 2C). The above data suggested that co-
incubation with the drug SQV and/or virus has synergistic effects
on the MDR1 gene as well as protein expression levels. Therefore,
we investigated whether augmented drug efflux function was seen
in HBMVEC exposed to HIV-1 (0.2 MOI) and SQV (0.3 mM).
Calcein-AM efflux assays were carried out in presence or absence
of verapamil (50 mM). Efflux function was fully suppressed when
cells were pre-incubated (15 min) with verapamil before the
addition of calcein-AM. The differences in calcein-AM fluores-
cence indicated the drug-efflux function under each treatment
condition. The change in calcein retention was almost 10-fold
(from 0.17 to 1.5) in cells co-exposed to HIV-1 and SQV, but was
less than 2-fold in both untreated cells and in cells exposed to
either the virus or SQV alone (Fig. 2D). This data clearly
established that coexposure to both drug and virus contribute to
the increased efflux activity of MDR1 in HBMVEC.
Immunofluorescence Microscopy Revealed Up-
regulation of Membrane MDR1 Levels Following Co-
exposure to HIV-1 and SQV in HBMVEC
To further corroborate our findings that HIV-1 and SQV co-
exposure results in increased MDR1 protein expression, cells were
treated with either HIV-1 (0.2 MOI) or SQV (1.0 mM) separately
or in combination for 48 hrs. Following which cells were stained
with antibodies to visualize the expression and sub-cellular
localization of MDR1 using a fluorescent microscope with
confocal imaging capability (Fig. 3). Cell nuclei were visualized
by DAPI staining (blue) and membrane staining was carried out
using WGA (red). A punctate staining pattern of MDR1 (in green)
was observed regardless of treatment (Fig. 3). To confirm
membrane localization of the protein, WGA was used to stain
the cell surface. Analysis of the Z-stack in overlaid pictures
indicated similar localization of WGA and MDR1, strongly
suggesting a membrane-associated pattern of MDR1 expression.
As compared to untreated cells (Fig. 3A), a more intense staining
HIV-1 Exposure on MDR-1 Efflux Function
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for MDR1 was observed when cells were exposed to either HIV-1
(Fig. 3B) or SQV (Fig. 3C) which was further increased by co-
exposure of HIV-1 and SQV (Fig. 3D). These observations
corroborated the gene and protein expression data, and indicated
that concomitant exposure to HIV-1 and SQV increases MDR1
expression at both the transcriptional and translational levels, and
facilitates their membrane localization which is required for their
drug-efflux functioning.
Co-exposure to HIV-1 and SQV Increased MDR1-
mediated Efflux of Radiolabeled Saquinavir (3H-SQV) in
HBMVEC
In order to determine whether the increased MDR1 expression
in cells coexposed to HIV-1 and SQV can indeed enhance the
functional activity of MDR1 in extruding HPIs from HBMVEC,
efflux function was measured by SQV retention, since it is a
known substrate of MDR1 [20]. Tritium labeled SQV (3H-SQV)
was used to monitor the drug efflux rates under untreated and
HIV-1-exposed conditions, in the presence or absence of
verapamil (50 mM). Intracellular radioactivity was measured as
counts per minute (CPM) after incubation under different
conditions and is considered as the level of 3H-SQV retention.
Compared to control conditions, there was a significant decrease
in SQV retention in the 3H-SQV and HIV-1 coexposed cells, and
significant increase (p,0.042) was observed when cells were
pretreated with verapamil (Fig. 4A). The combined exposure to
HIV-1 and SQV showed a 3.5-fold difference in 3H-SQV
retention with and without verapamil. The graphs show intracel-
lular 3H-SQV contents, normalized to the total protein contents in
respectively treatment wells. These drug-efflux assays clearly
exhibited the increased activity of MDR1 and SQV efflux under
HIV-1 and HPI exposed microenvironments. Since verapamil can
be a dual inhibitor of both MDR1 and MRPS, in order to further
verify the crucial role of MDR-1 transporter, 3H-SQV retention
was carried out in the presence of increasing concentrations (5–
50 mM) of verapamil or the MDR-specific inhibitor PSC-833
(Fig. 4B). The specific increase in MDR1-mediated efflux
following HIV-1 and SQV coexposure was clearly evident from
findings using PSC-833. The intracellular 3H-SQV retention was
considerably higher with PSC-833 compared to the verapamil
pretreated cells, at all tested conditions. This clearly indicated a
direct role for the MDR1 transporters in increased drug efflux
from HBMVEC.
siRNA-mediated MDR1 Inhibition Suppresses Drug-efflux
Function in HBMVEC Cells Co-exposed to HIV-1 and SQV
To further corroborate the role of MDR1 only, the HBVECs
were transfected with either a non-specific (NS) siRNA or a smart-
pool of siRNAs specific for the human MDR1 (30 nM each). After
Figure 1. Effect of HIV-1 exposure on MDR1 gene expression and efflux function in HBMVEC. (A) MDR-1, MRP-1 and MRP-2 gene
expression following exposure to HIV-1 (0.2 and 1.0 MOI) within 6 hrs post exposure was monitored by qRT-PCR. Data obtained in each sample was
normalized to GAPDH mRNA levels (internal control). Fold change in ABC-transporter gene expression with respect to that observed with MDR1 in
untreated cells (1.0) was calculated under each treatment condition and for each transporter. Data represent three independent experiments (n = 3)
where standard deviation (error bars) were calculated from triplicate samples and significant differences from controls are shown (*, p,0.05 and **
p,0.01). (B) MDR1 efflux function following exposure to HIV-1 (0.2 and 1.0 MOI) for 24 hrs. Verapamil and MK-571 were used as MDR1 and MRPs
blocker, respectively. Intracellular fluorescence was normalized to total protein content in cell lysates and change in calcein-AM retention is shown in
the bar graphs (*, p,0.05). (C) Comparative effects of conditioned medium (CM) from HIV-1-infected or PMA-stimulated HuT-78 T-cells on MDR1
gene expression. The RT-PCR products from HBMVEC control (1); Hut-78 CM (2); CM from HuT-78 cells treated with PMA (3); or CM from virus
producing HTLV-IIIB cells (4), are shown. (D) Effect of live HIV-1 (HTLV-IIIB CM) and heat inactivated HIV-1 (HTLV-IIIB CM-HI) on MDR1 gene expression.
The respective fold change in MDR1 gene expression was calculated with respect to GAPDH (internal control). A representative data from three
independent experiments, is shown.
doi:10.1371/journal.pone.0075374.g001
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24 hrs, cells were then exposed to the combined regimen of HIV-1
(0.2 MOI) and SQV (0.3 mM) for another 48 hrs. In one aliquot of
cells, we measured intracellular retention of 3H-SQV (Fig. 5A) and
in a parallel batch of cells we measured the extent of siRNA
mediated MDR1 inhibition by RT-PCR (Fig. 5B). Data obtained
in control (untreated) and HIV-1 plus SQV exposed HBMVEC
clearly depicted approximately 5-fold decrease in intracellular 3H-
SQV levels in cells transfected with the NS-siRNA, which was
similar to cells not transfected with any siRNAs (Fig. 5A).
However, the direct involvement of MDR1 in drug efflux was
clearly apparent by an almost total suppression of 3H-SQV efflux
in cells transfected with the MDR1 siRNA. Indeed, the MDR1
siRNAs were able to increase the intracellular 3H-SQV levels even
in untreated cells (p,0.05), indicating that HBMVEC possess a
MDR1 mediated constitutive drug-efflux mechanism which is
significantly up-regulated when exposed to HIV-1 and subse-
quently to the anti-HIV agent, SQV. The constitutive and
inducible expression of MDR1 is also clearly evident from the
semi-quantitative RT-PCR analysis (Fig. 5B). A detectable
expression was seen in untreated cells, HIV-1 exposure resulted
in a 2-fold increase, and co-exposures to HIV-1 and SQV caused a
higher than 5-fold increase in MDR1 mRNA levels. The potency
of siRNA mediated inhibition of MDR1 mRNA levels was evident
by the RT-PCR investigations in cells transfected with 30 nM of
random (NS) siRNA or MDR1 siRNA. There was a significant
inhibition of MDR1 gene in both control (60%), HIV-1 (56%) and
HIV-1 plus SQV (86%) exposed cells. This data clearly indicated
that MDR1 is specifically responsible for the increased drug-efflux
function in HIV-1 and SQV coexposed HBMVEC.
Discussion
The HIV-1 infected cells enter the brain very early following
infection via traversing the BBB endothelial cells and these
reservoirs persist within the CNS [21]. In this regard, finding
efficient ways to deliver HAART drugs to these brain reservoirs of
HIV-1 would be very crucial, to both suppress disease progression
and selection for drug resistance. Indeed, MDR1 is an important
drug-efflux mechanism expressed at the BBB, and is well known to
limit HAART efficacy in the CNS. Other transporters which co-
exist with MDR1 on the apical (blood) side, e.g. MRPs, might also
play a role in reducing drug efficacy. However, in our study the
major contribution of HIV-1 and SQV coexposure was found to
be via the MDR1 pump. The initial gene expression study which
Figure 2. Effect of HIV-1 and SQV coexposure on MDR1 expression and function in HBMVEC. (A) MDR1 gene expression in presence of
HIV-1 (0.2 MOI) and increasing concentration of SQV (0.3 and 1.0 mM). (B) Densitometric analysis of mRNA expression from Fig. 2A. (C) A
representative of western blot analysis data of MDR1 protein expression in untreated (1), HIV-1 (2), SQV (3) and HIV-1+ SQV (4) exposed cells. Beta (b)-
actin was used as internal control. The fold change analysis was done from three sets of independent western immunodetection studies. MDR1
protein expressions are normalized with b-actin expression in respective samples. (D) MDR1 mediated calcein-AM efflux in presence of HIV-1
(0.2 MOI) and/or SQV (0.3 mM). Grey bars indicate calcein retenition without inhibitor and black bars indicate calcein retention in presence of 50 mM
verapamil. Data shown are mean of three independent experiments (*, p,0.05 and **, p,0.01).
doi:10.1371/journal.pone.0075374.g002
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indicated the inductive effect of HIV-1 on transporter expressions,
was evident within six hours of exposing cells to virus-containing
media. There was an immediate induction of MDR1, and both
MRP-1 and MRP-3 genes. More importantly, MDR1 gene
expression was found to be significantly greater than the other two
transporters investigated in this study. The inductive role of HIV-1
was further investigated to determine whether other contributing
factors in the virus infected cellular supernatants can increase
MDR1 gene expression. However, supernatants from PMA-
stimulated HuT-78 lymphocytes, which produce inflammatory
cytokines, showed negligible effects on MDR1 expression.
Surprisingly, inflammatory factors could not induce MDR1 gene
expression as compared to that observed with supernatants
containing live virus, which was clearly evident when virus was
heat-inactivated in the supernantants (Fig. 1C). The MDR1 gene
expression with increasing concentration of virus (from 0.2 to
1.0 MOI) was further investigated towards MDR1-mediated efflux
function, which did not change significantly in cells exposed to
virus only. This definitely confirmed the role of live virus in MDR1
gene expression, and increased efflux activity of MDR1 is not
achieved by virus exposure only. Although, it has been reported
that MDR1 transporter function may depend on host cellular
factors such as inflammatory cytokines [22,23] and the HIV-1 Tat
protein has also been shown to increase MDR1 expression in a
murine model [24,25], our findings revealed new information
about the direct role of HIV-1 in MDR1 induction on HBMVEC,
especially under concomitant HPI exposure. According to our
knowledge, this is the first time a synergistic role of virus and anti-
Figure 3. Localization of MDR-1 (P-gp) protein in HIV-1 and SQV coexposed HBMVEC. A representative immunofluorescence microscopy
data of MDR-1 protein in HBMVEC following exposure to HIV-1 or SQV for 24 hrs is shown. Green punctate MDR-1 staining appeared in (A) untreated
cells, (B) cells exposed to SQV (1 mM), (C) cells exposed to HIV-1 (0.2 MOI) only, and (D) combined exposure of SQV and HIV-1. DAPI (blue) staining of
the nucleus and WGA (red) staining of cell plasma membrane are also shown. Image Magnification: 630X, scale bar: 21 mm.
doi:10.1371/journal.pone.0075374.g003
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HIV drugs has been documented on HBMVEC under in vitro
conditions. The current study also showed that inflammatory
factors from activated lymphocytes had negligible effects on
MDR1 induction which further indicates that the presence of
infectious HIV-1 is mainly responsible for the increase in MDR1
gene expression and concomitant exposure to the MDR1
substrates, such as the anti-HIV drugs, significantly increases
MDR1 activity.
Indeed, MDR1 substrates include most of the currently
available HPIs, and our previous research showed that SQV
induces MDR1 function [8]. The RT-PCR data showed a
significant increase of MDR1 following exposure to HIV-1 and/
or SQV. Moreover, with increasing concentration of SQV, we
observed that MDR1 expression was also increased. This data
indicated that MDR1 may definitely contribute to HAART drug
resistance mechanisms within the CNS reservoirs of HIV-1. The
MDR1 protein expression in HBMVEC was also changed under
different treatment conditions (Fig. 2C). Primarily, the synergistic
effect of drug and virus coexposure significantly increased the
MDR1 protein level, membrane localization, and efflux function.
Thus, our findings strongly suggest that the synergistic effect of
HIV-1 and SQV has induced certain cellular pathways that in
turn up-regulate MDR1 expression and efflux function, although
both of these factors were also seen to independently induce the
MDR1 protein level. Previous studies have shown the involvement
of different host cellular factors such as cytokines and chemokines
(TNF-a, IL-6, etc.) in MDR1 regulation in different human cell
types [4,10,24,26,27]. In HIV infected patients, inflammation
alters MDR1 expression in the brain and numerous chemokines
are believed to be the inflammatory mediators [28]. It was
observed that increase in chemokines in humans may increase the
MDR1 expression in BBB endothelial cells through different
signaling pathways, mainly the protein kinase-C (PKC) pathway
[6,29]. However, recent studies on rat brain capillaries indicated
that there is a network of signaling mechanisms that modulate
MDR1 activity involving TNF-a and IL-6 [29,30]. On the other
hand, HIV-1 Tat protein was also found to play an important role
in overexpressing MDR1 in rodent BBB by activating NF-kB [31].
The Tat-induced over expression of MDR1 in brain microvessels
clearly indicated the role of HIV-1 in MDR1 regulation. Likewise,
in the present study, the primary induction in MDR1 following
exposure to HIV-1 emphasizes that the virus mainly has an effect
on MDR1. So far, most of the previous HIV-1-related MDR1
induction studies were conducted in mice or rat cells that may not
be relevant in human cells, because most host immune responses
vary among species. The present study demonstrates that viral
induction of MDR1 expression and function can similarly occur in
primary human endothelial cells (HBMVEC), as well.
In the MDR1 intracellular localization study using confocal
microscopy, we have observed similar inductive effects of both
HIV-1 and SQV on MDR1 protein levels. The MDR1 (C-219)
antibody, which showed clear localization of MDR1 in the cell
(green punctate staining) suggested the increased distribution of
MDR1 at the cell membrane. A punctate staining pattern for
MDR1 on cell membranes has been described previously to be
due to their localization at plasma membrane lipid raft like
structures, and may also be explained by the presence of MDR1 in
vesicles that are closely associated with the plasma membrane
[32,33]. Compared to untreated cells, treatment of SQV and
HIV-1 separately induced membrane localization of the MDR1
protein; however, with combined treatment, there was a much
higher increase, and is clearly evident in the representative image
(Fig. 3). It is possible that both HIV-1 and SQV behave as
inducing agents for MDR1 gene and protein expression and
combination of these two factors has additive effect on MDR1
function and increased membrane localization. Bauer et al (2005)
[34], have mentioned that there are three different factors such as
location, potency and substrate specificity which render MDR1 a
key component of drug regulation in the CNS, and our studies
with HIV-1 and SQV exposed HBMVEC demonstrated that all
three mechanisms may be involved in increasing drug-efflux
function.
The luminal location (on blood side) of MDR1 on BBB makes it
very important in the efflux of certain drug substrates back into the
blood stream. The substrate specificity of MDR1 on certain HPIs
and on nucleoside/nucleotide analogs (NRTIs) causes the drug
Figure 4. A comparative analysis of 3H-SQV efflux in HBMVECs
exposed to HIV-1 and/or SQV in presence of verapamil or PSC-
833. (A) Effect of verapamil (50 mM) on 3H-SQV retention in HBMVEC
exposed to HIV-1 and/or SQV for 24 hrs. Under each treatment
condition, intracellular 3H-SQV was measured in presence of verapamil
and compared with control (without inhibitor). The radioactivity in cell
lysates were normalized to total cell protein content (CPM/ug of
protein) and data from three independent experiments are presented
as fold changes. (B) Effect of increasing concentrations (5–50 mM) of
verapamil or PSC-833 on 3H-SQV retention in HBMVEC exposed to HIV-1
and SQV for 24 hrs. Data are representative of three separate
independent experiments carried out in triplicates (*, p,0.05 and **,
p,0.01).
doi:10.1371/journal.pone.0075374.g004
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efflux problem at the BBB to be a formidable barrier. Considering
the complex host cellular signaling pathways in response to HIV-1,
investigating whether cellular factors or viral factors are respon-
sible for MDR1 function becomes challenging. In the present
study, we have observed low endogenous expression and efflux
function of MDR1 in primary HBMVEC, although both SQV
and HIV-1 act as inducing factors on the efflux function. The
calcein-AM and 3H-SQV retention studies showed high functional
activity of MDR1 and significant inhibition by verapamil alone.
There is a possibility that verapamil might block other transporters
(MRPs), which are present on the luminal side (blood side), as well.
However, considering the gene expression profile, it is evident that
the MDR1 activity is much higher than the other transporters. In
order to be certain that our present observation is indeed MDR1
mediated, the MDR1 specific blocker, PSC-833 was used and
compared with verapamil. In a dose response study with both
verapamil and PSC-833, it was evident that by increasing
concentration of PSC-833, the MDR1 specific blockade was more
prominent. This observation confirmed our present investigation
of MDR1 specific induction of drug-efflux by HIV-1 and SQV co-
exposure. Furthermore, the MDR1 specific siRNA inhibition
study assured the fact that exposure of HIV-1 and/or SQV
Figure 5. Effect of MDR1 specific siRNA on HIV-1 and SQV induced drug efflux in HBMVEC. (A) Fold change in 3H-SQV retention (CPM/mg
of protein) in HBMVEC are shown in control (untreated) and HIV-1 (0.2 MOI) and SQV (0.3 mM) exposed cells. Data from non-transfected, and in cells
transfected with either a random (NS) or an MDR1 specific siRNA, are shown. Data are representative of three independent experiments carried out in
triplicates (*, p,0.05 and **, p,0.001). (B) Relative inhibition of MDR1 gene expression in MDR1 siRNA transfected and control (random) siRNA
transfected cells are shown by semi-quantitative RT-PCR. Change in MDR1 gene expression following treatment with HIV-1 (0.2 MOI) and HIV-1+SQV,
in control and siRNA transfected cells, are shown. Changes in band intensities of PCR products for MDR1 mRNA were normalized to the GAPDH mRNA
levels, in respective samples, and fold changes obtained compared to control (1.0) are shown.
doi:10.1371/journal.pone.0075374.g005
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induces MDR1 specific gene expression and efflux function. Our
findings on the effect of virus and drugs on MDR1 efflux function
indicates a potential mechanism of HIV-1 drug resistance in the
CNS and ultimately resulting in HAART failure for the patients
undergoing therapy. Therefore, our study may give insight
regarding the pharmacokinetics of other HAART drugs, which
are substrates for MDR1, as well.
It is understood that the function of BBB in drug transport
regulation in the CNS is a complex mechanism and MDR1 plays
an important role in this process [36]. Indeed, MDR1 has been
mostly studied in the context of cancer drug resistance [37,38] and
there are only a few other previous publications indicating its
crucial role in HAART drug efflux from the CNS [3,7,8,20,39].
Previous studies on MDR1 did not establish a direct correlation
between mRNA and protein expression with MDR1-mediated
efflux function [10,35]; however, our present study indicates that
HIV-1 and SQV alone induce expression of this transporter at the
transcriptional level only, and concomitant exposure may be
needed for significant increases in function. Indeed, functional
activity for these transporters is only possible if membrane
localization occurs, as shown in our immunofluorescence micros-
copy studies (Fig. 3). In infected microenvironments, the viral
secretary proteins Tat, Nef, Vpu may induce certain host cellular
pathways that in turn upregulates MDR1 membrane expression
[40,41]. The HIV-1 Tat-mediated MAP-kinase activation can also
upregulate MRP1 expression in mice [31]. Since the MAPK
signaling pathways activate multiple downstream second messen-
gers such as ERK1/2, JNK and p38 MAPK pathways, these may
also induce MDR1, and/or other transporters, as well [42]. In
fact, it is well known that the activated p38 MAPK pathway leads
to release of certain inflammatory cytokines from BBB like IL-2,
IL-4, IL-6 and TNF-a. These cytokines/chemokines have been
implicated in facilitating HIV-1 entry into the CNS through
transmigrating via the brain endothelial cell barriers [4,41,43];
however, their direct role in activating the BBB endothelial cell
drug-efflux mechanisms need to be investigated. Hayashi et al
(2006) [44] demonstrated that HIV-1 Tat can induce MDR1
expression in mice. Moreover, Tat and HIV-1 gp120 both induces
oxidative stress in brain endothelial cells and cause degradation of
vascular basement membrane and vascular tight junction even
without the presence of intact HIV virion [40,45,46]. Although the
molecular mechanisms of these regulators are not fully understood,
as cell regulatory signals including oxidative stress and inflamma-
tory cytokine secretion, may also contribute to drug efflux activity
[11,23,47], investigations on the involvement of other host or viral
factors in MDR1 regulation within HIV-1 infected foci of the
brain needs to be understood. The mechanism of MDR1 based
drug regulation at the BBB, where a number of factors may
contribute to drug-efflux function, will need to be investigated
towards strategies for their specific inhibition. Indeed, our siRNA
based study clearly indicated the major involvement of MDR1 in
drug-efflux from cells coexposed to HIV-1 and SQV. This
implicates that a specific inhibition of MDR1 transporters may
provide a clear therapeutic advantage within infected regions of
the brain.
Conclusions
The current study suggests that the MDR1 transporters in the
HBMVEC are mainly involved in regulating the entry of HPIs
within the CNS. As occurring in HIV-1 infected patients, the
concomitant presence of HIV-1-mediated inductive signaling on
MDR1 gene expression and the presence of MDR1 substrates
such as the HPIs, may act as significant stimulators for the MDR1
mediated drug-efflux function. We observed that HIV-1 exposure
alone is not sufficient for increased MDR1 function and co-
exposure to HPIs, e.g. saquinavir and/or soluble factors present in
HIV-1-infected microenvironments, may be necessary to manifest
the increased MDR1 mediated drug-efflux. These data also
suggested that the specific inhibition of MDR1 via siRNA or PSC-
833 may increase drug entry into the HBMVEC, and thus anti-
HIV-1 efficacy within the HIV-1 infected CNS reservoirs.
Therefore, targeted suppression of MDR1 (P-gp) expression at
the HIV-1 infected reservoirs that overexpress this transporter
may introduce novel therapeutic strategies to inhibit drug-efflux
from the brain. The utility of siRNA based inhibitory strategies
targeted towards the HIV-1-infected CNS foci will also be devoid
of the side effects of a generalized inhibition of multiple ABC-
transporters or MDR1 inhibition at non-infected sites.
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